Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
This article was originally published in The Pink Sheet
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.
You may also be interested in...
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.